Kymera Investor Presentation Deck

KYMERA KYMERA ● ● Kymera's 2023 Objectives Collaborate with Sanofi to initiate KT-474 Phase 2 Trials Publish results of KT-474 Phase 1 Trial including patient cohort Demonstrate KT-413 clinical anti-tumor activity in patients Demonstrate KT-333 clinical anti-tumor activity in patients Initiate KT-253 Phase 1 Trial in solid and heme tumors Establish KT-253 clinical proof-of-mechanism in patients Deliver at least 2 new DC/IND from the preclinical pipeline Expand novel molecular glue franchise ©2023 KYMERA THERAPEUTICS, INC. PAGE 8

View entire presentation